close
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

ImmunoPrecise Antibodies Ltd. - Common Stock (NQ:IPA)

2.070 UNCHANGED
Last Price Updated: 4:00 PM EDT, Sep 3, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about ImmunoPrecise Antibodies Ltd. - Common Stock

< Previous 1 2 3 4 5 6 Next >
News headline image
ImmunoPrecise Antibodies And InterSystems Partner To Leverage AI In Life Sciences, Transforming Patient Care With Accelerated Discovery And Delivery Of Treatments
Via ACCESSWIRE
News headline image
InterSystems and IPA’s Subsidiary BioStrand Collaborate to Unveil the Innovative Integration of Vector Search with LENSai for AI-Driven Healthcare Applications
From ImmunoPrecise Antibodies Ltd.
Via Business Wire
News headline image
IPA Acquires the Carterra LSA® Instrument to Enhance Antibody Discovery and Bolster Its AI Developments
From ImmunoPrecise Antibodies Ltd.
Via Business Wire
News headline image
IPA Reports Financial Results and Recent Business Highlights for Third Quarter Fiscal Year 2024*
From ImmunoPrecise Antibodies Ltd.
Via Business Wire
News headline image
ImmunoPrecise Antibodies (NASDAQ:IPA) Subsidiary BioStrand Introduces Breakthrough AI Model In Life Sciences, Harnessing LLM Stacking And HYFT Technology
Via ACCESSWIRE
News headline image
IPA’s subsidiary BioStrand Unveils Major Breakthrough in Life Sciences with Advanced Foundation AI Model Utilizing LLM Stacking and HYFT Technology
From ImmunoPrecise Antibodies Ltd.
Via Business Wire
News headline image
IPA to Report Financial Results and Recent Business Highlights for Third Quarter Fiscal Year 2024 on March 14, 2024
From ImmunoPrecise Antibodies Ltd.
Via Business Wire
News headline image
ImmunoPrecise Antibodies (NASDAQ:IPA) Is Changing How We Look At The Complex World Of Antibody Discovery
Via ACCESSWIRE
News headline image
ImmunoPrecise Antibodies Reports A 19.9% Revenue Increase As It Launches The Next Phase Of LENSai Portal And SaaS Platforms
Via ACCESSWIRE
News headline image
IPA Reports Financial Results and Recent Business Highlights for Second Quarter Fiscal Year 2024*
From ImmunoPrecise Antibodies Ltd.
Via Business Wire
News headline image
IPA Announces Closing of $1.265 Million Public Offering of Common Shares
From ImmunoPrecise Antibodies Ltd.
Via Business Wire
News headline image
ImmunoPrecise Antibodies Welcomes Mitch Levine To Its Board Of Directors, To Announce Quarterly Results On December 14
Via ACCESSWIRE
News headline image
IPA Announces Pricing of $1.1 Million Public Offering of Common Shares
From ImmunoPrecise Antibodies Ltd.
Via Business Wire
News headline image
IPA Announces Proposed Public Offering of Common Shares
From ImmunoPrecise Antibodies Ltd.
Via Business Wire
News headline image
ImmunoPrecise Antibodies Ltd. Announces Key Board and Board Committee Chair Appointments and Second Quarter 2024 Earnings Release Call
From ImmunoPrecise Antibodies Ltd.
Via Business Wire
News headline image
ImmunoPrecise’s BioStrand(R) Unifies Diverse Data Modalities, Launches AI-Driven Platform For Enhanced Drug Discovery
Via ACCESSWIRE
News headline image
BioStrand® Unveils a Revolutionary Approach to Biological Sequence Retrieval: A Fusion of Natural Language Processing and Database Research
From ImmunoPrecise Antibodies Ltd.
Via Business Wire
News headline image
IPA’s Subsidiary, BioStrand, Provides an Update on LENSai™
From ImmunoPrecise Antibodies Ltd.
Via Business Wire
News headline image
IPA Provides Update on Growth Strategy and Recent Share Price Movement
From ImmunoPrecise Antibodies Ltd.
Via Business Wire
News headline image
Overcoming the Information Integration Dilemma: Revolutionizing The Fusion Of Complex Biological Data
Via ACCESSWIRE
News headline image
How ImmunoPrecise Antibodies Is Leveraging AI To Revolutionize Antibody Research
Via ACCESSWIRE
News headline image
ImmunoPrecise Antibodies Announces CFO Transition
From ImmunoPrecise Antibodies Ltd.
Via Business Wire
News headline image
IPA Reports Financial Results and Recent Business Highlights for First Quarter Fiscal Year 2024
From ImmunoPrecise Antibodies Ltd.
Via Business Wire
News headline image
IPA to Report Financial Results and Recent Business Highlights for First Quarter Fiscal Year 2024 on September 14, 2023
From ImmunoPrecise Antibodies Ltd.
Via Business Wire
News headline image
IPA Announces Board Refreshment
From ImmunoPrecise Antibodies Ltd.
Via Business Wire
News headline image
IPA Responds to 13D Filing
From ImmunoPrecise Antibodies Ltd.
Via Business Wire
News headline image
ImmunoPrecise Antibodies Invites Investors and Stakeholders to Exclusive Interview with Market Radius Research
From ImmunoPrecise Antibodies Ltd.
Via Business Wire
News headline image
ImmunoPrecise Reports Financial Results and Recent Business Highlights for Full Fiscal Year 2023
From ImmunoPrecise Antibodies Ltd.
Via Business Wire
News headline image
IPA to Report Financial Results and Recent Business Highlights for Fourth Quarter and Fiscal Year End 2023 on July 7th, 2023.
From ImmunoPrecise Antibodies Ltd.
Via Business Wire
“Convergence of AI and Biology: Companies at the Forefront of Transformative Innovations”:- IPA, MRKR, PRAX , RMED
Via AB Newswire
Topics Artificial Intelligence
< Previous 1 2 3 4 5 6 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Starting at $3.75/week.

Subscribe Today